ClinicalTrials.gg

How we know

Every link on this study, and who decided it

The study on the left, the conditions and drugs this site links it to, and on each link the judgments that made or checked it, by day and by judge. The top row is the record itself: each new version seen since tracking began. Dashed lines are links the registry record does not make itself. Select a link to see everything judged on it, or a mark for one decision with its reason and evidence.

Why Serplulimab is on this study

  • The record lists it as a treatment, written “HLX10, Trastuzumab and Chemotherapy”.
  • Claude Opus 5.5 judged it tested: part of what the study tests. Nov 2, 2026, 3:40 AM UTC
  • The role rule says the same.
  • So Serplulimab's page lists this study under “Testing it”.
  • The record changed after this reading. Until it is read again, the page keeps the reading and says so.
3 links0 made here, not in the record7 judgments2 judges (the rules as one: Rule based)2 record changes seen2 read an older version
Claude Opus 5.5Rule basedRecord updated on ClinicalTrials.govReplaced, or read an older version
Oct 19Oct 26Nov 2Nov 9Nov 16Nov 23TodayNCT05311189Study of HLX10, Trastuzumaband Chemotherapy inFirst-line Treatment ofHER2-positiveRecurrent/MetastaticGastric CancerShanghai Zhongshan HospitalPhase 2 · active not recruitinRECORDThe record itselfVersions seen nightly since Sep 25, 2…›Nov 8 · ClinicalTrials.gov record · MeSH filing re-derivedNov 12 · ClinicalTrials.gov record · Version of 2026-11-12Nov 12 · Rule based · Reading set asideNov 16 · Rule based · Read againRead againCONDITIONSStomach NeoplasmsNo longer in the registry's filing›As of now · Rule based · Main conditionMain conditionDRUGSSerplulimabEntry “HLX10, Trastuzumab and Chemoth…›Nov 2 · Claude Opus 5.5 · TestedNov 18 · Rule based · TestedTestedTrastuzumabEntry “HLX10, Trastuzumab and Chemoth…›Nov 2 · Claude Opus 5.5 · BackgroundNov 18 · Rule based · TestedTested

Times are in your time zone; a day marked “day only” kept no time. The graph scrolls sideways on a narrow screen; every mark is also in the list below.

All judgments on this study

WhenLinkJudgeDecisionState
1 version of the record seen on ClinicalTrials.gov, Nov 12 · changes seen, not judgments
Nov 2SerplulimabClaude Opus 5.5TestedRead an older version
Nov 2TrastuzumabClaude Opus 5.5BackgroundRead an older version
Nov 8The record itselfClinicalTrials.gov recordMeSH filing re-derivedRecord change
Nov 12The record itselfRule based · nightly checkReading set asideCurrent
Nov 16The record itselfRule based · nightly checkRead againCurrent
Nov 18SerplulimabRule based · role ruleTestedCurrent
Nov 18TrastuzumabRule based · role ruleTestedCurrent
As of nowStomach NeoplasmsRule based · main-condition ruleMain conditionCurrent

The rules, in plain words

“Rule based” means one of these decided, not a model or a person. Each runs every night over every study.

Which drugs a study tests

Reads each treatment the study lists and the arms it is in. A drug only in the experimental arm is tested. A drug in every arm while something else changes between the arms is given beside it. A drug only in the control arm is the comparator. Placebo, procedures and usual care are known by name.

Where the whole record has been read, that reading's answer replaces the rule's.

What a study is mainly about

Starts from the first condition ClinicalTrials.gov files the study under. It moves to a narrower one only when the study's own title or listed conditions name it, and sets aside terms the registry often files by mistake. A study open to many cancers is not placed under one of them unless its title names it.

Checked against studies judged one by one; the study page says when it differs from the registry.

When a study changes after it was read

Every night, studies whose record changed are compared with the last reading. A change to sites or dates leaves the reading as it is; a reworded entry keeps it; a change to the treatments or conditions marks it to be read again.

Until it is read again, the page shows the last reading and says so.